InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (20 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
20
T+90 hit rate
0%
T+90 mean return
-17.7%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Hallal David, Director. Officer active across 6 companies, notably iTeos Therapeutics, Inc.. In total, 34 filings have been logged. Split: 0 buy · 20 sells. Total volume traded: €12.2m. History available since 20 December 2021. The latest transaction was disclosed on 16 April 2026 (Cession). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Hallal David
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations34 total
30,615 shares@ US$49.57450.022% mcap100.0% of flowCommon StockSEC:0001104659-26-045581:0
128,004 shares0Common StockSEC:0001104659-26-013580:0
57,450 shares@ US$42.7062.0% of flowCommon StockSEC:0001104659-26-004221:0
205,000 shares0Common StockSEC:0001457477-25-000004:0
38,227 shares@ US$4.30100.0% of flowCommon StockSEC:0000950170-25-083410:0
250,000 shares0Common StockSEC:0001104659-25-041457:0
13,500 shares0Common StockSEC:0001415889-24-018627:0
58,178 shares0Class A Common StockSEC:0001415889-24-016896:0
35,000 shares0Common StockSEC:0000950170-24-070600:0
23,443 shares0Class A Common StockSEC:0001209191-23-038189:0
35,000 shares0Common StockSEC:0001209191-23-029102:0
600,000 shares@ US$8.4521.9% of flowCommon StockSEC:0000899243-22-033994:0
400,000 shares@ US$7.352312.6% of flowCommon StockSEC:0000899243-22-032297:0
3,253,796 shares@ US$4.6162.1% of flowCommon StockSEC:0000899243-22-027173:0
4,227 shares@ US$5.32950.1% of flowCommon StockSEC:0000899243-22-026519:0
9,945 shares0Class A Common StockSEC:0001209191-22-038097:0
5,968 shares@ US$4.2313.3% of flowCommon StockSEC:0001209191-22-036137:0
65,725 shares@ US$3.668429.3% of flowCommon StockSEC:0000899243-22-021183:0
4,227 shares@ US$5.873.0% of flowCommon StockSEC:0000899243-22-015395:0
40,481 shares@ US$7.553736.1% of flowCommon StockSEC:0000899243-22-010762:0
17,100 shares@ US$8.005215.8% of flowCommon StockSEC:0000899243-22-003144:0
20,000 shares@ US$4.3043.3% of flowCommon StockSEC:0001209191-21-070993:0
619 sharesCommon Stock, par value $.0001 per shareSEC:0000899866-16-000245:0
10 sharesCommon Stock, par value $.0001 per shareSEC:0000899866-16-000245:1
41,136 sharesCommon Stock, par value $.0001 per shareSEC:0000899866-16-000245:2
25 of 34 declarations
About Hallal David
David Hallal serves as a Director at iTeos Therapeutics, Inc., Allovir, Inc., and Seer, Inc. He brings significant expertise in the biopharmaceutical sector. His experience allows him to contribute effectively to strategic discussions and decision-making within the boards. David is recognized for his ability to assess market opportunities and formulate informed recommendations for the company's development.
